Two hundred patients with self-reported knee pain were randomized to receive collagen peptide (CP) supplementation or placebo supplementation with maltodextrin for 12 weeks. The primary outcome was knee pain which was evaluated using the Visual Analogue Scale (VAS). Additional outcomes of interest included knee pain measured using the Numeric Pain Rating Scale (NPRS), knee function via the Knee injury and Osteoarthritis Outcome Score (KOOS), and the Lysholm questionnaire. Furthermore, the following blood and bone markers were also evaluated: serum interleukin 6 (IL-6), tumour necrosis factor alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1), C-reactive protein (CRP), C-terminal cross-linked telopeptide type II collagen (CTX-II), procollagen II C-terminal propeptide (P2CP), Carboxy-terminal telopeptides (CTX), and procollagen I intact N-terminal (PINP). Also, compliance of patients was also evaluated. All outcomes were measured at baseline and 12 weeks follow-up. Results of this study revealed that the change from baseline in all outcomes were not statistically significantly different between the CP supplementation and placebo groups (p>0.05 for all). Compliance was high in both groups, with 99.6% in the CP group and 99.4% in the placebo group, with no statistically significant differences observed (p=0.29).